Clostridioides

Bonumose says FDA Sides With High Fructose Corn Syrup Producers and Against Consumers, By Suppressing Truthful Information About Tagatose

Retrieved on: 
Giovedì, Maggio 19, 2022
Diabetes, Chinese Academy of Sciences, HFCS, Public health, Tooth decay, Bias, Freedom of Information Act 2000, Dentistry, Tagatose, Food, NFP, Sickle cell disease, Solution, Health, Psicose, World Economic Forum, Crop protection, Infant, Method, FDA, Philosophy, Hyperglycemia, Industry, Ice cream, K-1 visa, Time, Information, Dietary fiber, Dietary supplement, Immunity, Freedom, Dental plaque, Adoption, HMF, POLITICO, Clostridioides, Fructose, Science, Internal, CEO, Pharmaceutical industry

Internal FDA documents discovered via the Freedom of Information Act indicate a potential FDA bias against health-focused innovation and in favor of industrial corn sweetener producers.

Key Points: 
  • Internal FDA documents discovered via the Freedom of Information Act indicate a potential FDA bias against health-focused innovation and in favor of industrial corn sweetener producers.
  • Tagatose feeds beneficial bacteria in the gut, which makes it healthy for the gut microbiome.
  • If the FDA actually cared about human health, it would encourage, not discourage, the broad adoption of tagatose.
  • Beyond food ingredients, Bonumose also is developing enzyme solutions for dietary supplements, crop protection, animal nutrition, and other globally-significant industries.

Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update

Retrieved on: 
Venerdì, Aprile 29, 2022
MRSA, QIDP, DNA, Securities and Exchange Commission (Philippines), Infection, Clostridioides, DRSP, Patient, Annual report, FDA, Clostridioides difficile (bacteria), GAIN, Enterococcus, Food, Gram-positive bacteria, Clostridioides difficile infection, Company, Act, Gram, Private Securities Litigation Reform Act, CDI, Security (finance), Marketing, CDC, VRE, Firmicutes, Methicillin-resistant Staphylococcus aureus, Fast Track, GPSS, IIIC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, Pharmaceutical industry, Actinobacteria

It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.

Key Points: 
  • It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
  • The Company successfully completed Phase 1 and Phase 2a clinical trials of ibezapolstat.
  • Acurx is currently enrolling patients in its Phase 2b vancomycin-controlled efficacy study in a 1:1 randomized trial of a total of 64 patients with CDI.
  • Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.

Evidence Validates Effectiveness of Splashblocker in Reducing Toilet Plume

Retrieved on: 
Giovedì, Aprile 28, 2022
Research, Oncology, Infectious Diseases, Hospitals, Construction & Property, Clinical Trials, Science, Nursing, Building Systems, Medical Supplies, Practice Management, Health, Food and Environmental Hygiene Department, OCN, Dangerous, Virus, CEO, Time, Scanning mobility particle sizer, PPE, LLC, Patient, Journal, Inhalation, National Institute, Method, Caregiver, Clostridioides difficile (bacteria), University of Oklahoma Health Sciences Center, SARS, Bacteria, NIOSH, Â, Job, Organization, Nursing, Doctor of Philosophy, Aerosol, Coronavirus, ONS, University, Risk, Occupational safety and health, National Institute for Occupational Safety and Health, HDS, Infection, Personal protective equipment, Particle size, Safety, Pharmaceutical industry, Clostridioides, Health

Since most hospital toilets do not have a lid, flushing the toilet creates bioaerosols which can contaminate surfaces and cause potential inhalation of particles.

Key Points: 
  • Since most hospital toilets do not have a lid, flushing the toilet creates bioaerosols which can contaminate surfaces and cause potential inhalation of particles.
  • In our aerosol lab we performed a series of experiments to evaluate the effectiveness of the Splashblocker in reducing particles of various sizes, said Changjie Cai, PhD, who led the study.
  • We now have scientific evidence to demonstrate how the Splashblocker significantly reduces exposure and environmental contamination.
  • We are excited by the proof of the significant reduction in aerosolized particles, said Brian Crawford, CEO & Co-Founder of Splashblocker, LLC.

The second part of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada

Retrieved on: 
Giovedì, Aprile 7, 2022
Company, Vomiting, Physiology, Clostridioides difficile (bacteria), Data monitoring committee, Heart, Virulence, Intubation, Gram-positive bacteria, Clinical trial, CDC, Infection, Bacteria, Centers for Disease Control and Prevention, Global health, QIDP, Clostridioides difficile infection, Incidence, Ileus, CEO, CDI, ISIN, Perforated ulcer, Review, Collection, Toxic megacolon, Physician, Disease, Subclinical infection, Center, DSMB, FDA, University, Patient, Medical device, Pharmaceutical industry, Vaccine, Antibiotics, Dietary supplement, Microbiology, Clostridioides

This second country will accelerate patient enrollment in this Phase II clinical trial of DNV3837 in Clostridioides difficile infections.

Key Points: 
  • This second country will accelerate patient enrollment in this Phase II clinical trial of DNV3837 in Clostridioides difficile infections.
  • Thus, all 40 patients who will be included in the trial will receive DNV3837.
  • Dr. Thomas Louie, Professor of Microbiology and Infectious Diseases at the University of Calgary (Canada) and a world expert on Clostridioides difficile, will lead and report on the trial in Canada.
  • Today, DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infections, one of the worlds first emergencies.

Acurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m. EDT

Retrieved on: 
Mercoledì, Marzo 16, 2022
Recurrence, IIIC, MRSA, Patient, Biotechnology, VRE, Private Securities Litigation Reform Act, Chief executive officer, Infection, Plasma, Conference, FDA, Fireside, Infectious Diseases Society of America, Firmicutes, Methicillin-resistant Staphylococcus aureus, Clostridioides difficile infection, Q&A, Primary energy, Health information technology, NASDAQ, EDT, Kepler-86, Tobacco Products Scientific Advisory Committee, Clostridioides, Gram-positive bacteria, Financial services, Company, Got Game Entertainment, DRSP, CEO, Charles M. Vest, Clostridioides difficile (bacteria), QIDP, CDI, DNA, Fireside chats, Gram, Enterococcus, Marketing, Pharmaceutical industry, Health care, Actinobacteria

Mr. Luci will be presenting during the Fireside Chat with Acurx Pharmaceuticals, Inc. at 9:30 am ET on Monday, March 28, 2022.

Key Points: 
  • Mr. Luci will be presenting during the Fireside Chat with Acurx Pharmaceuticals, Inc. at 9:30 am ET on Monday, March 28, 2022.
  • The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.
  • About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • However, while we may elect to update these forward- looking statements at some point in the future, we specifically disclaim any obligation to do so.

PDI HEALTHCARE INTRODUCES NOVEL DISINFECTANTS TO BETTER PROTECT HEALTHCARE ENVIRONMENTS DURING CRITICAL TIME

Retrieved on: 
Martedì, Marzo 8, 2022
Risk, Subclinical infection, Infection, Infectious Diseases Society of America, ESKAPE, Patient, Klebsiella pneumoniae, Staphylococcus aureus, Hospital, Research, PDI, HAI, Korea Disease Control and Prevention Agency, Norovirus, Methicillin, Clostridioides difficile (bacteria), The New England Journal of Medicine, Enterobacteriaceae, Solution, Multistable perception, Disinfectant, Acinetobacter baumannii, COVID-19, Candida auris, Vancomycin, Klebsiella aerogenes, New Delhi metallo-beta-lactamase 1, Clostridioides, Environment, Enterobacter, Hydrogen peroxide, CDC, MDR, VRE, EPA, Health, Center, Severe acute respiratory syndrome coronavirus 2, CAD, Pseudomonas aeruginosa, No, MRSA, Pharmaceutical industry, Sewage, Eyeish

"Given PDI's long legacy of pioneering important infection prevention solutions, we are proud to offer healthcare facilities a solution that protects surfaces and equipment from recontamination around the clock."

Key Points: 
  • "Given PDI's long legacy of pioneering important infection prevention solutions, we are proud to offer healthcare facilities a solution that protects surfaces and equipment from recontamination around the clock."
  • "Today's vulnerable healthcare environment has prompted an urgent need to strengthen infection prevention programs to better safeguard patients and staff," said Watts.
  • "Multiple layers of defense, including effective and easy-to-use disinfectants, will continue to be key to helping prevent infections, save costs, and improve care."
  • PDI has three divisions, PDI Healthcare, Sani Professional and PDI Contract Manufacturing.

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

Retrieved on: 
Lunedì, Marzo 7, 2022
Capsule, Exotoxin, CDI, Clostridioides difficile (bacteria), DRSP, The New England Journal of Medicine, Inflammation, Clostridioides, Extrapyramidal system, Firmicutes, Kepler-86, Private Securities Litigation Reform Act, Enterococcus, Vancomycin, Wall, Germination, Metabolism, Company, Incidence, IDSA, Risk, Pharmacokinetics, Infection, IIIC, QIDP, Virulence, Marketing, Maintenance, Gram-positive bacteria, Epithelium, Methicillin-resistant Staphylococcus aureus, Liver, VRE, NASDAQ, Clinical, Gram, Recurrence, Patient, GUH, Hospital, Death, Actinobacteria, Microorganism, GI, DNA, Safety, Lessa, Structural Classification of Proteins database, Diarrhea, Mortality, MRSA, Pharmaceutical industry, Dietary supplement

David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

Key Points: 
  • David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:
    About the Ibezapolstat Phase 2 Clinical Trial.
  • In this cohort, 10 patients with diarrhea caused by C. difficile were treated with ibezapolstat 450 mg orally, twice daily for 10 days.
  • About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.

Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints

Retrieved on: 
Martedì, Marzo 1, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Macdonald, Clostridioides difficile infection, Risk, PFE, U.S. Securities and Exchange Commission, CDC, The New England Journal of Medicine, Systematic review, Death, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Twitter, Pain, AES, Diagnosis, Center, Diarrhea, Annual report, Inc., COVID-19, CDI, Clostridioides difficile (bacteria), Facebook, Safety, NYSE, Disease, Meta-analysis, Clostridioides, Ageing, Person, Food, Vaccine, Clostridium, Senior, Șaeș, LinkedIn, Hospital, Recurrence, Science, FDA, YouTube, Patient, Research, Program, Vaccination, Incidence, Pharmaceutical industry, Pfizer, the CLOVER Trial, Pfizer: Breakthroughs That Change Patients’ Lives, THE CLOVER TRIAL, PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES

Pfizer Inc. (NYSE:PFE) today announced results from the CLOVER trial (CLOstridium difficile Vaccine Efficacy TRial), a pivotal Phase 3 study evaluating its Clostridioides difficile (C. difficile) vaccine candidate (PF-06425090) in the prevention of C. difficile infection (CDI).

Key Points: 
  • Pfizer Inc. (NYSE:PFE) today announced results from the CLOVER trial (CLOstridium difficile Vaccine Efficacy TRial), a pivotal Phase 3 study evaluating its Clostridioides difficile (C. difficile) vaccine candidate (PF-06425090) in the prevention of C. difficile infection (CDI).
  • All laboratory-confirmed CDI cases are among persons with diarrhea who seek medical care and have a stool specimen collected and tested for C. difficile.
  • A highly favorable potential benefit was noted in reducing the duration and severity of disease.
  • Pfizer will further evaluate data from the trial and determine next steps for our C. difficile vaccine program.

DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections

Retrieved on: 
Giovedì, Gennaio 6, 2022
Ileus, Clostridioides difficile infection, Toxic megacolon, Vomiting, Safety, QIDP, Intubation, Subclinical infection, Review, Company, Patient, Virulence, Physician, Phase, Medical director, Gram-positive bacteria, COVID, Perforated ulcer, Bacteria, Infection, Centers for Disease Control and Prevention, FDA, ISIN, DSMB, Disease, CDI, Physiology, Global health, Center, Incidence, COVID 19, Data monitoring committee, Heart, CDC, Collection, Pharmaceutical industry, Vaccine, Antibiotics, Clostridioides

The DSMB considered that the benefit/risk balance of antibiotic therapy with DNV3837 was in favor of continuing the recruitment in this trial.

Key Points: 
  • The DSMB considered that the benefit/risk balance of antibiotic therapy with DNV3837 was in favor of continuing the recruitment in this trial.
  • Thus, all patients included in the trial (40 in total) will receive DNV3837.
  • Dr. Yannick Pltan, DEINOVE's Medical Director, commented: This favorable opinion from the DSMB is an important step for the development of DNV3837.
  • Today, DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infections, one of the worlds first emergencies.

Tillotts Pharma AG announces that DIFICLIRTM (fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID

Retrieved on: 
Mercoledì, Dicembre 8, 2021
Health, Infectious Diseases, Clinical Trials, Research, Pharmaceutical, Science, Medical microbiology, Disease, CDI, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, News, Risk factor, ESCMID, Recurrence, Goldenberg, Dis, Clostridioides difficile infection, Microbiota, Infection, PMID, Acquisition, Plasma protein binding, Clostridioides, Meta-analysis, ECDC, IDSA, Patient, IBD, Consultant, Mortality, OTC, Human, Tesco international operations, Clostridium difficile, Systematic review, Vancomycin, European Centre for Disease Prevention and Control, Lancet, University, Tablet, Guideline, Society, Wes Tillott, Fidaxomicin, CDAD, Health care, MD, Adult, RNA, Clinical trial, Trial of the century, Vaccine, Pharmaceutical industry, DIFICLIRTM, Tillotts, Zeria, DIFICLIRTM, TILLOTTS, ZERIA

Despite the endemic nature of C. difficile in many healthcare settings, sustained clinical cure and prevention of recurrence are achievable treatment goals for CDI.

Key Points: 
  • Despite the endemic nature of C. difficile in many healthcare settings, sustained clinical cure and prevention of recurrence are achievable treatment goals for CDI.
  • European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
  • Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
  • Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 300 employees in Switzerland and abroad.